The Transformation of Clinical Trial Strategies in the Era of Decentralized and Hybrid Opportunities
The Transformation of Clinical Trial Strategies in the Era of Decentralized and Hybrid Opportunities
Sponsored by:
Sponsored by:
More from Clinical Trials
• By
Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.
• By
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
• By
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
• By
The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.
More from R&D
In partnership with
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
In partnership with
Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics.
In partnership with
Insights from Novotech on Evolving Trends Impacting Global Clinical Development
Sponsored by:
Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system